Status:
RECRUITING
Brain Function and Psychological Changes Related to Cell Therapy for Autoimmune Hemolytic Anemia
Lead Sponsor:
Institute of Hematology & Blood Diseases Hospital, China
Collaborating Sponsors:
Tianjin University
Conditions:
CAR T-cell Therapy
Autoimmune Hemolytic Anemia
Eligibility:
All Genders
18-65 years
Brief Summary
Cell therapy is an innovative treatment with significant efficacy in hematologic and certain autoimmune diseases. Although it offers potential benefits for autoimmune hemolytic anemia (AIHA), it may r...
Eligibility Criteria
Inclusion
- Diagnosis of AIHA
- Subjects will receive cell therapy such as CAR T-cell therapy
- Male or female, aged 18-65 years
- Willing and able to comply with the requirements for this study and written informed consent
Exclusion
- History of psychiatric illness
- History of severe brain disease
- Subjects that the investigator believes have other reasons that make them unsuitable for inclusion in this study
Key Trial Info
Start Date :
February 25 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06921980
Start Date
February 25 2025
End Date
December 31 2026
Last Update
August 5 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Regenerative Medicine Center
Tianjin, Tianjin Municipality, China